

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADO
NEWS	4	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	5	MAR 02	GBFULL: New full-text patent database on STN
NEWS	6	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	9	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	10	MAR 22	PATDPASPC - New patent database available
NEWS	11	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	12	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	13	APR 04	EMBASE - Database reloaded and enhanced
NEWS	14	APR 18	New CAS Information Use Policies available online
NEWS	15	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAPLUS and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	16	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAPLUS
NEWS	17	MAY 23	GBFULL enhanced with patent drawing images
NEWS	18	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	19	JUN 06	The Analysis Edition of STN Express with Discover! (Version 8.0 for Windows) now available
NEWS	20	JUN 13	RUSSIAPAT: New full-text patent database on STN
NEWS	21	JUN 13	FRFULL enhanced with patent drawing images
NEWS	22	JUN 27	MARPAT displays enhanced with expanded G-group definitions and text labels
NEWS	23	JUL 01	MEDICONF removed from STN
NEWS	24	JUL 07	STN Patent Forums to be held in July 2005
NEWS	25	JUL 13	SCISEARCH reloaded
NEWS EXPRESS			JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS. HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:12:18 ON 20 JUL 2005

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:12:31 ON 20 JUL 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 JUL 2005 HIGHEST RN 856046-16-7

DICTIONARY FILE UPDATES: 19 JUL 2005 HIGHEST RN 856046-16-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> E "NS1619"/CN 25

E1	1	NS1-BINDING PROTEIN-LIKE PROTEIN (HUMAN)/CN
E2	1	NS104/CN
E3	0 -->	NS1619/CN
E4	1	NS2 (NONSTRUCTURAL, 2) PROTEIN (INFLUENZA A VIRUS STRAIN A/CHARLOTTESVILLE/31/95(H1N1) GENE NS2)/CN
E5	1	NS2 (NONSTRUCTURAL, 2) PROTEIN (INFLUENZA A VIRUS STRAIN ENGLAND/1/53 VERO CELL-ADAPTED)/CN
E6	1	NS2 (NONSTRUCTURAL, 2) PROTEIN (INFLUENZA A VIRUS STRAIN ENGLAND/1/53)/CN
E7	1	NS2 AND NS3 ANTIGEN FRAGMENT (HEPATITIS NON-A NON-B VIRUS CLONE C14-3)/CN
E8	1	NS2 AND NS3 ANTIGEN FRAGMENT (HEPATITIS NON-A NON-B VIRUS CLONE C4-1)/CN

E9	1	NS2 ANTIGEN (HEPATITIS C VIRUS PATIENT #4)/CN
E10	1	NS2 ANTIGEN (HEPATITIS C VIRUS PATIENT #6)/CN
E11	1	NS2 PROTEIN (HUMAN CORONAVIRUS OC43 STRAIN ATCC VR-759 ISOLATE
OC43 GENE NS2)/CN		
E12	1	NS2 PROTEIN (HUMAN HEPATITIS C VIRUS JAPANESE VARIANT HCV-N)/CN
E13	1	NS2 PROTEIN (MURINE HEPATITIS VIRUS STRAIN DVIM GENE 2A)/CN
E14	1	NS2-3 PROTEASE/CN
E15	1	NS2-NS3 PROTEASE/CN
E16	1	NS20S/CN
E17	1	NS21A/CN
E18	1	NS21NB/CN
E19	1	NS23/CN
E20	1	NS2A PROTEIN (HUMAN CORONAVIRUS OC43 STRAIN ATCC VR-759 ISOLATE
OC43 GENE NS2A)/CN		
E21	1	NS2B-NS3 PROTEASE/CN
E22	1	NS3 (BLUETONGUE VIRUS 1 STRAIN 1 CLONE S1REF GENE NS3)/CN
E23	1	NS3 (BLUETONGUE VIRUS 1 STRAIN 5012/VACCINE/1 CLONE S1VAC GENE
NS3)/CN		
E24	1	NS3 (BLUETONGUE VIRUS 1 STRAIN S1/1999/1 CLONE S1F1 GENE NS3)/CN
E25	1	NS3 (BLUETONGUE VIRUS 11 STRAIN 11 CLONE S11REF GENE NS3)/CN

=> E "NS 1619"/CN 25

E1	1	NS 160/CN
E2	1	NS 1608/CN
E3	1 -->	NS 1619/CN
E4	1	NS 1652/CN
E5	1	NS 17/CN
E6	1	NS 17550/CN
E7	1	NS 1764/CN
E8	1	NS 1784/CN
E9	1	NS 18/CN
E10	1	NS 18-2/CN
E11	1	NS 1840/CN
E12	1	NS 190/CN
E13	1	NS 199999/CN
E14	1	NS 1C/CN
E15	1	NS 1D/CN
E16	1	NS 1V/CN
E17	4	NS 2/CN
E18	1	NS 2 (HEAT STABILIZER)/CN
E19	1	NS 2 (PHARMACEUTICAL)/CN
E20	1	NS 2 (POLYESTER)/CN
E21	1	NS 2 (POLYESTER), POLYMER WITH CELLULOSE ACETATE BUTANOATE AND
CORONATE T 80/CN		
E22	1	NS 2 (STABILIZER)/CN
E23	4	NS 20/CN
E24	1	NS 20 (INSULATOR)/CN
E25	1	NS 20 (POLYOL)/CN

=> S E3

L1 1 "NS 1619"/CN

=> DIS L1 1 SQIDE

THE ESTIMATED COST FOR THIS REQUEST IS 6.15 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 153587-01-0 REGISTRY

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-  
5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


OTHER NAMES:

CN NS 1619

FS 3D CONCORD

MF C15 H8 F6 N2 O2

SR CA  
 LC STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CHEMCATS, CSCHEM, EMBASE, IMSDRUGNEWS, IMSRESEARCH, MEDLINE, PHAR, PROMT, PROUSDDR, TOXCENTER, USPATFULL  
 DT.CA CAPLUS document type: Journal; Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)  
 RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)  
 RLD.NP Roles for non-specific derivatives from non-patents: PREP (Preparation)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

61 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 61 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus  
 COST IN U.S. DOLLARS  
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
7.30	7.51

FILE 'CAPLUS' ENTERED AT 14:13:26 ON 20 JUL 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Jul 2005 VOL 143 ISS 4  
 FILE LAST UPDATED: 19 Jul 2005 (20050719/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 11  
 L2 61 L1

=> s apoptosis or (cell death)  
 102867 APOPTOSIS  
 1937360 CELL

1707527 CELLS  
2577871 CELL  
    (CELL OR CELLS)  
123677 DEATH  
10064 DEATHS  
130897 DEATH  
    (DEATH OR DEATHS)  
51933 CELL DEATH  
    (CELL(W) DEATH)  
L3 125792 APOPTOSIS OR (CELL DEATH)

=> s l3 and l2

L4 5 L3 AND L2

=> d ibib 1-3

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2005:22533 CAPLUS  
DOCUMENT NUMBER: 142:367129  
TITLE: Mitochondrial Ca<sup>2+</sup>-Activated K<sup>+</sup> Channels in Cardiac  
Myocytes  
AUTHOR(S): Sato, Toshiaki; Saito, Tomoaki; Saegusa, Noriko;  
Nakaya, Haruaki  
CORPORATE SOURCE: Department of Pharmacology, Chiba University Graduate  
School of Medicine, Chiba, Japan  
SOURCE: Circulation (2005), 111(2), 198-203  
CODEN: CIRCAZ; ISSN: 0009-7322  
PUBLISHER: Lippincott Williams & Wilkins  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2003:690151 CAPLUS  
DOCUMENT NUMBER: 140:192597  
TITLE: The K<sup>+</sup> channel openers diazoxide and NS1619 induce  
depolarization of mitochondria and have differential  
effects on cell Ca<sup>2+</sup> in CD34<sup>+</sup> cell line KG-1a  
AUTHOR(S): Korper, Sixten; Nolte, Florian; Rojewski, Markus  
Thomas; Thiel, Eckhard; Schrezenmeier, Hubert  
CORPORATE SOURCE: Medizinische Klinik III (Hamatologie, Onkologie und  
Transfusionsmedizin), Universitätsklinikum Benjamin  
Franklin, Freie Universität Berlin, Berlin, Germany  
SOURCE: Experimental Hematology (New York, NY, United States)  
(2003), 31(9), 815-823  
CODEN: EXHMA6; ISSN: 0301-472X  
PUBLISHER: Elsevier Science Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2003:683275 CAPLUS  
DOCUMENT NUMBER: 140:70880  
TITLE: Cilostazol prevents tumor necrosis  
factor- $\alpha$ -induced cell death  
by suppression of phosphatase and tensin homolog  
deleted from chromosome 10 phosphorylation and  
activation of Akt/cyclic AMP response element-binding  
protein phosphorylation  
AUTHOR(S): Hong, Ki Whan; Kim, Ki Young; Shin, Hwa Kyoung; Lee,  
Jeong Hyun; Choi, Jae Moon; Kwak, Yong-Geun; Kim, Chi

CORPORATE SOURCE: Dae; Lee, Won Suk; Rhim, Byung Yong  
 Department of Pharmacology, Pusan National University,  
 Pusan, S. Korea  
 SOURCE: Journal of Pharmacology and Experimental Therapeutics  
 (2003), 306(3), 1182-1190  
 CODEN: JPETAB; ISSN: 0022-3565  
 PUBLISHER: American Society for Pharmacology and Experimental  
 Therapeutics  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib 4-5

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:300434 CAPLUS  
 DOCUMENT NUMBER: 138:297626  
 TITLE: Method for inducing selective cell  
 death of malignant cells by activation of  
 calcium-activated potassium channels (KCa)  
 INVENTOR(S): Black, Keith L.; Ningaraj, Nagendra S.  
 PATENT ASSIGNEE(S): Cedars-Sinai Medical Center, USA  
 SOURCE: U.S. Pat. Appl. Publ., 30 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003072748	A1	20030417	US 2001-976961	20011012
WO 2004078920	A2	20040916	WO 2003-US6176	20030227
WO 2004078920	A3	20050303		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-976961 A 20011012

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:305307 CAPLUS  
 DOCUMENT NUMBER: 131:128233  
 TITLE: Potassium channels and neurodegenerative diseases  
 AUTHOR(S): Rundfeldt, Chris  
 CORPORATE SOURCE: Dept. of Pharmacology I, Corporate R and D, ASTA  
 Medica GmbH, Radebeul, D-01445, Germany  
 SOURCE: Drug News & Perspectives (1999), 12(2), 99-104  
 CODEN: DNPEED; ISSN: 0214-0934  
 PUBLISHER: Prous Science  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English  
 REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib kwic 5

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:305307 CAPLUS  
DOCUMENT NUMBER: 131:128233  
TITLE: Potassium channels and neurodegenerative diseases  
AUTHOR(S): Rundfeldt, Chris  
CORPORATE SOURCE: Dept. of Pharmacology I, Corporate R and D, ASTA  
Medica GmbH, Radebeul, D-01445, Germany  
SOURCE: Drug News & Perspectives (1999), 12(2), 99-104  
CODEN: DNPEED; ISSN: 0214-0934  
PUBLISHER: Prous Science  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB A review, with 43 refs. Many different insults and mechanisms can lead to neurodegeneration. Potassium channel openers may play a role in counteracting or preventing this damage. A heterogeneous array of potassium channels, classified according to their electrophysiol. properties, has been identified. Different potassium channels are involved in several steps within the pathophysiol. cascade that ultimately leads to cell death; therefore, several potassium channel openers may interfere with different steps within the neurodegenerative cascade. However, it is possible that in case of severe insults potassium channel opening may not lead to neuroprotection, due to the fact that potassium channels are already endogenously activated and the extracellular potassium concentration is already very high. Thus, further channel opening may have no addnl. pos. effects. Selective drugs for individual channel subtypes should be used in predictive models of neurodegeneration; however, the currently known potassium channel openers are few and nonselective. The classes of drugs that need to be explored include potassium channel openers of the ATP-sensitive, high-conductance calcium-sensitive, and inward rectifier or leakage types. Selective openers for inward rectifier potassium channels are currently not available, although activation of 5-HT1A receptors results in the induction of an inwardly rectifying potassium current. Potent neuroprotective properties have been described for different 5-HT1A agonists in models of focal and global ischemia. Retigabine, a leakage-current potassium channel opener, has been shown to have neuroprotective effects in animal models of neurodegeneration. Of the currently available potassium channel openers, retigabine and BAY-X-3702 are active at nontoxic doses. Further research is needed to develop selective, well-tolerated potassium channel openers.

IT 94470-67-4, Cromakalim 141797-92-4, NS 004 144980-77-8, BAY-X-3702  
150812-12-7, Retigabine 153587-01-0, NS-1619 184653-84-7,  
SB-204269

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(potassium channels, potassium channel openers and neurodegenerative diseases)

=> file pctfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.49	23.00
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.73	-0.73

FILE 'PCTFULL' ENTERED AT 14:15:10 ON 20 JUL 2005

COPYRIGHT (C) 2005 Univentio

FILE LAST UPDATED: 19 JUL 2005 <20050719/UP>  
MOST RECENT UPDATE WEEK: 200528 <200528/EW>  
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

=> s NS1619 or (NS () 1619)  
10 NS1619  
38456 NS  
144 NSES  
38568 NS  
(NS OR NSES)  
2735 1619  
17 NS (W) 1619  
L5 24 NS1619 OR (NS (W) 1619)

=> s apoptosis or (cell death)  
17362 APOPTOSIS  
197049 CELL  
171438 CELLS  
223851 CELL  
(CELL OR CELLS)  
39315 DEATH  
6389 DEATHS  
41819 DEATH  
(DEATH OR DEATHS)  
16516 CELL DEATH  
(CELL(W) DEATH)  
L6 24909 APOPTOSIS OR (CELL DEATH)

=> s 15 and 16  
L7 11 L5 AND L6

=> s 17 not @py>2001  
'2001' NOT A VALID FIELD CODE  
0 @PY>2001  
L8 11 L7 NOT @PY>2001

=> s 17 not py>2001  
391444 PY>2001  
L9 2 L7 NOT PY>2001

=> d ibib 1-2

L9 ANSWER 1 OF 2 PCTFULL COPYRIGHT 2005 Univentio on STN  
ACCESSION NUMBER: 2001078709 PCTFULL ED 20020826  
TITLE (ENGLISH): TREATMENT OF NEURODEGENERATIVE DISEASE  
TITLE (FRENCH): TRAITEMENT DES MALADIES NEURODEGENERATIVES  
INVENTOR(S): BAMDAD, R., Shoshanna;  
BAMDAD, Cynthia, C.  
PATENT ASSIGNEE(S): MINERVA BIOTECHNOLOGIES CORPORATION  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001078709	A2	20011025

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL  
IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG  
MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ  
TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD



SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY  
 DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF  
 CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US12484 A 20010412  
 PRIORITY INFO.: US 2000-60/196,497 20000412  
 US 2000-60/214,221 20000623  
 US 2000-60/248,890 20001115

L9 ANSWER 2 OF 2 PCTFULL COPYRIGHT 2005 Univentio on STN  
 ACCESSION NUMBER: 2000056145 PCTFULL ED 20020515  
 TITLE (ENGLISH): ORGAN ARREST, PROTECTION AND PRESERVATION  
 TITLE (FRENCH): ARRET, PROTECTION ET PRESERVATION D'ORGANES  
 INVENTOR(S): DOBSON, Geoffrey, Phillip  
 PATENT ASSIGNEE(S): JAMES COOK UNIVERSITY;  
 DOBSON, Geoffrey, Phillip  
 LANGUAGE OF PUBL.: English  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000056145	A1	20000928

# DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ  
 DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS  
 JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN  
 MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT  
 TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ  
 UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES  
 FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA  
 GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-AU226 A 20000322  
 PRIORITY INFO.: AU 1999-PP 9414 19990323  
 AU 1999-PQ 4199 19991123

=> d his

(FILE 'HOME' ENTERED AT 14:12:18 ON 20 JUL 2005)

FILE 'REGISTRY' ENTERED AT 14:12:31 ON 20 JUL 2005

E "NS1619"/CN 25  
 E "NS 1619"/CN 25

L1 1 S E3

FILE 'CAPLUS' ENTERED AT 14:13:26 ON 20 JUL 2005

L2 61 S L1  
 L3 125792 S APOPTOSIS OR (CELL DEATH).  
 L4 5 S L3 AND L2

FILE 'PCTFULL' ENTERED AT 14:15:10 ON 20 JUL 2005

L5 24 S NS1619 OR (NS () 1619)  
 L6 24909 S APOPTOSIS OR (CELL DEATH)  
 L7 11 S L5 AND L6  
 L8 11 S L7 NOT @PY>2001  
 L9 2 S L7 NOT PY>2001

=> s cancer? or tumor? or neoplas?

70033 CANCER?  
 58772 TUMOR?  
 20120 NEOPLAS?

L10 87552 CANCER? OR TUMOR? OR NEOPLAS?

=> s l10 and l9

L11 1 L10 AND L9

=> d ibib

L11 ANSWER 1 OF 1 PCTFULL COPYRIGHT 2005 Univentio on STN  
ACCESSION NUMBER: 2001078709 PCTFULL ED 20020826  
TITLE (ENGLISH): TREATMENT OF NEURODEGENERATIVE DISEASE  
TITLE (FRENCH): TRAITEMENT DES MALADIES NEURODEGENERATIVES  
INVENTOR(S): BAMDAD, R., Shoshanna;  
BAMDAD, Cynthia, C.  
PATENT ASSIGNEE(S): MINERVA BIOTECHNOLOGIES CORPORATION  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001078709	A2	20011025

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR  
CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL  
IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG  
MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ  
TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD  
SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY  
DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF  
CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US12484 A 20010412  
PRIORITY INFO.: US 2000-60/196,497 20000412  
US 2000-60/214,221 20000623  
US 2000-60/248,890 20001115

=> d kwic 1 19

L9 ANSWER 1 OF 2 PCTFULL COPYRIGHT 2005 Univentio on STN

DETD . . . pindolol  
B-169 BRL 37344 sodium  
B-017 NWZ piperazine (2:1 ratio of 1-(4-hydroxy methoxyphenyl)-1,2-ethanediol and diethyldiazene)  
A-142 R(-)+atenolol  
C-118 cimetidine  
M-133 (+a-methyl norepinephrine  
O-100 oxotremorine methiodide  
P-155 (-)-physostigmine  
A-134 4-aminopyridine  
N-170 NS-1619 (1,3-dihydro-1-[2-hydroxy (trifluoromethyl)phenyl] (trifluoromethyl)-2H-benzimidazol one)  
E-120 erbstatin analog  
Structures of the above-listed compositions are shown in FIGs. 3  
The names of structures A. . .

FIG. 6 shows structures of 4-aminopyridine, NS-1619 (1,3-dihydro [2-hydroxy (trifluoromethyl)phenyl] (trifluoromethyl)-2H-benzimidazol one), (-)-physostigmine, erbstatin analog, spironolactone, valproic acid sodium, phenylephrine hydrochloride, urapidil, 5-methyl, phentolan-fine mesylate, YS-035 hydrochloride (3,3',4,4'-tetramethoxy-N-methyl-diphenethylamine hydrochloride),. . .

Subjects for whom methods of treatment with NS-1619 in this aspect of the invention

are not intended are those who are diagnosed with conditions which  
already call for treatment  
with. . .

(those wells that remain pink) indicates that the APP protein  
was effected by the drug in one of the aforementioned ways. Cell  
death due to drug toxicity  
would obviously effect APP production, and may cause a well to remain  
pink. For this  
reason, all wefis. . .

CLMEN. . . of a medicament for the treatment or prevention of a disease  
associated with  
fibril formation or aberrant protein aggregation.  
117. Use of NS-1619, or a homolog, analog, or  
derivative thereof, for the manufacture of a  
medicament for the treatment or prevention of a disease. . .

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	10.58	33.58
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.73

STN INTERNATIONAL LOGOFF AT 14:18:15 ON 20 JUL 2005